Bamlanivimab

From EverybodyWiki Bios & Wiki


Bamlanivimab
INN: Bamlanivimab
Monoclonal antibody
Type?
TargetSpike protein of SARS-CoV-2
Identifiers
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}

Bamlanivimab or LY-CoV555 is an experimental drug developed by the American biotechnology company Eli Lilly and Company.[1] The drug was granted an emergency use approval by the FDA in November 2020. 900,000 doses had been bought by the US federal government as of early December 2020.[2]

Drug description[edit]

The drug is a potent, neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. The aim is to block viral attachment and entry into human cells, thus neutralizing the virus, and help preventing and treating COVID-19.[3]

Research history[edit]

Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.[3]

In early October 2020, Eli Lilly and Company submitted a Emergency Use Authorization (EUA) request to the FDA.[3]

On 28 October 2020, Eli Lilly and Company announced in had struck a deal with the U.S. government to supply 300,000 vials of Bamlanivimab 700 mg for $375 million.[3]

On 9 November 2020, the drug was granted an emergency-use authorization by U.S. drug regulators for treating Covid-19[4]

See also[edit]

  • Casirivimab/imdevimab another monoclonal antibody treatment for Covid-19.

References[edit]

  1. "Bamlanivimab COVID-19 Treatment". www.precisionvaccinations.com.
  2. "Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19 | Eli Lilly and Company". investor.lilly.com.
  3. 3.0 3.1 3.2 3.3 >"Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19". www.lilly.com/.
  4. "Eli Lilly Covid Antibody Drug Gets FDA Emergency Clearence". November 9, 2020 – via www.bloomberg.com.

External links[edit]




This article "Bamlanivimab" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Bamlanivimab. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.